Dapagliflozin exhibits class I antiarrhythmic effects which suppress action potential formation in human atrial cardiomyocytes
Event: ESC Congress 2022
Topic: Cellular Mechanisms of Arrhythmias
Session: Insights into arrhythmia mechanisms
ESC 365 is supported by
